BCRX Stock News & Catalysts – BioCryst Pharmaceuticals

FEATURED

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: 2026 Jefferies Global

Summary

Nov 4, 2026, 4:01 PM ·Globe Newswire

RECENT

BioCryst Reports Third Quarter 2026 Financial Results

— Total net revenue of $180.3 million and ORLADEYO® net revenue of $174.8 million — — Operating profit of $53.3 million and Non-GAAP operating profit of $86.5 million — — Maintained Full Year 2026 ORLADEYO revenue

Nov 4, 2026, 7:00 AM ·Globe Newswire

BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting

—New data highlight BioCryst's commitment to advancing a portfolio of therapies for people living with HAE— RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.

Oct 29, 2026, 7:00 AM ·Globe Newswire

BioCryst to Report Third Quarter 2026 Financial Results on November 4

RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2026 financial results on Wednesday,

Oct 21, 2026, 4:01 PM ·Globe Newswire

BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE

—Expands BioCryst portfolio of targeted oral prophylactic therapy options to meet patients’ individual needs and preferences— —ORLADEYO is the first and only targeted oral prophylactic therapy with options for HAE

Oct 21, 2026, 7:00 AM ·Globe Newswire

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

—Supports BioCryst’s evolution toward a more disciplined R&D model centered on external innovation— RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Oct 5, 2026, 7:00 AM ·Globe Newswire

BioCryst to Present at Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Morgan Stanley 24th Annual Global Healthcare

Sep 1, 2026, 7:00 AM ·Globe Newswire

BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan

— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to <12 years in Japan — RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals,

Aug 25, 2026, 7:01 AM ·Globe Newswire

BioCryst Reports Second Quarter 2026 Financial Results

— Total net revenue of $218.3 million and ORLADEYO® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million — — Maintained Full Year 2026

Aug 5, 2026, 7:00 AM ·Globe Newswire

BioCryst to Report Second Quarter 2026 Financial Results on August 5

RESEARCH TRIANGLE PARK, N.C., July 22, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2026 financial results on Wednesday, August

Jul 22, 2026, 7:00 AM ·Globe Newswire

BioCryst Appoints David W. Jenkins as Chief Scientific Officer

RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ("BioCryst" or the "Company") today announced the appointment of David W. Jenkins, MA, PhD,

Jul 15, 2026, 7:00 AM ·Globe Newswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired

Jul 2, 2026, 7:00 AM ·Globe Newswire

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

—Advances strategic shift toward a disciplined research model prioritizing external innovation to accelerate rare disease pipeline growth— —Completes enrollment in Phase 3 ALPHA-ORBIT for navenibart, largest pivotal

Jun 29, 2026, 7:00 AM ·Globe Newswire

BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

— Growing body of ORLADEYO® clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations — New post hoc analysis of

Jun 12, 2026, 7:00 AM ·Globe Newswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst's board of directors granted nine newly-hired

Jun 9, 2026, 4:05 PM ·Globe Newswire

BioCryst Pharmaceuticals, Inc. BCRX · News